First Line of Treatment Medications to dominate the Tuberculosis Therapeutics Market through 2028
Global
Tuberculosis Therapeutics Market to be driven by the increasing prevalence of
tuberculosis during the forecast period.
According to TechSci Research report, “Tuberculosis
Therapeutics Market - Global Industry Size, Share, Trends, Opportunity,
and Forecast, 2018-2028F”, Global
Tuberculosis Therapeutics Market is anticipated to grow at an impressive rate
in the forecast period, 2024-2028. This can be attributed to the
increase in new treatment options for tuberculosis (TB) in the last few years
which show promise in improving patient outcomes and reducing the spread of the
disease. Additionally, supportive government policies and schemes is further
expected to support the growth of global tuberculosis treatment market. One
example of a government initiative to develop new TB therapies is the United
States' National Institute of Allergy and Infectious Diseases (NIAID) TB
Research Unit. This unit is focused on developing new drugs and vaccines for
TB, with a particular emphasis on drug-resistant strains of the bacteria. The
NIAID TB Research Unit works with researchers from around the world to identify
promising drug candidates and test them in clinical trials. Another government
initiative is the TB Alliance, a non-profit organization that was created to
develop new TB therapies. The TB Alliance is focused on developing drugs that
are effective against drug-resistant TB and that can be taken for shorter
periods of time than current treatments. The organization has several drugs in
clinical trials, including a drug called Pretomanid, which was recently
approved by the US Food and Drug Administration (FDA) for the treatment of
drug-resistant TB.
However, one of the potential challenges
that hampers the growth of global tuberculosis therapeutics market is emergence
of drug-resistant strains of the bacteria. This occurs when the bacteria that
cause TB mutate and become resistant to the antibiotics used to treat the
disease. According to the World Health Organization (WHO), there were an
estimated 465,000 cases of multidrug-resistant TB (MDR-TB) in 2020, and an
additional 182,000 cases of rifampicin-resistant TB (RR-TB), which is a type of
MDR-TB. Treating drug-resistant TB is much more difficult and costly than
treating drug-susceptible TB, and there are limited treatment options
available, which can lead to poor patient outcomes. Another challenge related
to TB therapeutics is the long duration of treatment. Standard treatment for
drug-susceptible TB involves taking a combination of antibiotics for six
months, while treatment for drug-resistant TB can take up to two years. This
long duration of treatment can be a barrier to treatment adherence, which can
lead to treatment failure, disease relapse, and the development of drug
resistance, thereby slowing down the growth of global tuberculosis therapeutics
market in the coming years.
Browse over XX market data Figures
spread through XX Pages and an in-depth TOC on "Tuberculosis Therapeutics Market.”
Global Tuberculosis
Therapeutics Market can be segmented by disease type, by therapy, by route of
administration, by dosage form, by distribution channel, and by region. Based
on disease type, global tuberculosis therapeutics market can be split into
active tuberculosis and latent tuberculosis. The active tuberculosis segment
dominated the market in 2022 and is expected to continue maintaining its
dominance through 2028. This can be attributed to the rising prevalence of
active tuberculosis among the population. The latent tuberculosis segment is expected to show
the fastest growth rate over the forecast period since in this type the person
suffers from the disease without even knowing about it. This form of infection
is generally categorized by being present in the body without making the person
feel sick.
By therapy,
the global tuberculosis therapeutics market can be divided into first line
therapy and second line therapy. The first line therapy segment is expected to
dominate the global tuberculosis therapeutics market through 2028. This can be
ascribed to the development of a large number of first line therapeutic drugs
such as isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), streptomycin
(SM), and ethambutol (EMB). While second line therapy segment is expected to
register the highest growth in the global tuberculosis therapeutics market
owing to the increasing instances of drug resistance among the population.
Major companies operating in the Global Tuberculosis
Therapeutics Market are:
- AstraZeneca,
Plc.
- Johnson
& Johnson
- Eli
Lilly And Company
- Mylan
N.V.
- Teva
Pharmaceutical Industries Ltd.
- Sanofi
SA
- Novartis
AG
- Sun
Pharmaceutical Industries Ltd.
- Pfizer
Inc.
Download Free Sample Report
Customers can also request
for 10% free customization on this report.
“Governments and companies around the world are working to develop new TB
therapies to address the significant challenges posed by this disease. These
initiatives are focused on developing drugs that are effective against
drug-resistant TB, that can be taken for shorter periods of time than current
treatments, and that have fewer side effects, this in turn is further expected
to support the growth of global tuberculosis therapeutics market in the coming
years” said Mr. Karan Chechi, Research Director with TechSci Research, a
research based global management consulting firm.
Tuberculosis Therapeutics Market - Global
Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented
By Disease Type (Active Tuberculosis, Latent Tuberculosis), By Therapy (First
Line Therapy, Second Line Therapy), By Route of Administration (Oral,
Parenteral, Others), By Dosage Form (Tablets, Capsules, Injection, Others), By
Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By
Region and Competition”, has evaluated
the future growth potential of Tuberculosis Therapeutics Market and provides
statistics & information on market size, structure, and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in global Tuberculosis Therapeutics Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com